RemeGen Announces Positive Phase III Results for Telitacicept in SLE
China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...
BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...
Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia
Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...
Beijing Launches HIV Precision Medicine Standardization Project
On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...
Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive...
Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline
China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi...
Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...
Lepu Medtech Prices GDR Offering for International Expansion
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced...
Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D
China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money...
NHSA Launches Expert Review for 2025 NRDL Update in China
The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...
Daehwa Pharmaceutical Files NDA for Liporaxel in China for Gastric Cancer Treatment
South Korea’s Daehwa Pharmaceutical (KOSDAQ: 067080) has announced the filing of a New Drug Application...
Antengene’s ATG-101 Receives Orphan Drug Designation for Pancreatic Cancer
China-based biotech Antengene Corp., Ltd (HKG: 6996) has announced that its pipeline candidate ATG-101, a...
Ascletis Pharma and Roche Terminate Promotion Agreement for Pegasys
China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant...
Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing
Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company...
Everest Medicines Appoints Rogers Yongqing Luo as New CEO
China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers...
Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage
Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...
Shenzhen Vivolight Raises RMB 100 Million in Series D1 Financing for Laser Therapy Development
China-based laser diagnosis and treatment specialist Shenzhen Vivolight Medical Device & Technology Co., Ltd reportedly...
Best Covered Raises RMB 100 Million in Series A+ Funding for Cognitive Impairment Solution
Shanghai-based digital cognitive impairment solution provider Best Covered reportedly raised RMB 100 million (USD 14.2...
US Blocks Asymchem’s Acquisition of Snapdragon Chemistry
US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...